# Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea

> **NCT01150942** · PHASE3 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 205 (actual)

## Conditions studied

- Japanese Encephalitis

## Interventions

- **BIOLOGICAL:** JE vaccine

## Key facts

- **NCT ID:** NCT01150942
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-09
- **Final completion:** 2013-02
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2014-01-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01150942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01150942, "Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01150942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*